Tiemann Investment Advisors LLC raised its holdings in Colgate-Palmolive (NYSE:CL) by 2.4% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,455 shares of the company’s stock after buying an additional 150 shares during the period. Tiemann Investment Advisors LLC’s holdings in Colgate-Palmolive were worth $442,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. BB&T Corp boosted its position in Colgate-Palmolive by 1.2% in the 1st quarter. BB&T Corp now owns 274,086 shares of the company’s stock valued at $18,786,000 after buying an additional 3,129 shares during the period. Ffcm LLC boosted its position in Colgate-Palmolive by 5.6% in the 4th quarter. Ffcm LLC now owns 63,206 shares of the company’s stock valued at $3,762,000 after buying an additional 3,325 shares during the period. Nachman Norwood & Parrott Inc boosted its position in Colgate-Palmolive by 1.9% in the 1st quarter. Nachman Norwood & Parrott Inc now owns 11,101 shares of the company’s stock valued at $761,000 after buying an additional 209 shares during the period. Strs Ohio boosted its position in Colgate-Palmolive by 1.9% in the 1st quarter. Strs Ohio now owns 415,958 shares of the company’s stock valued at $28,509,000 after buying an additional 7,713 shares during the period. Finally, River & Mercantile Asset Management LLP purchased a new position in Colgate-Palmolive in the 4th quarter valued at approximately $7,765,000. 75.66% of the stock is owned by institutional investors.
In related news, VP Justin Skala sold 92,643 shares of Colgate-Palmolive stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $70.78, for a total transaction of $6,557,271.54. Following the sale, the vice president now directly owns 163,653 shares in the company, valued at approximately $11,583,359.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen I. Sadove sold 8,000 shares of Colgate-Palmolive stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $71.55, for a total transaction of $572,400.00. Following the sale, the director now owns 39,441 shares in the company, valued at $2,822,003.55. The disclosure for this sale can be found here. Insiders sold a total of 338,711 shares of company stock worth $24,020,415 over the last 90 days. Company insiders own 1.14% of the company’s stock.
Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, April 26th. The company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.01. Colgate-Palmolive had a net margin of 15.08% and a negative return on equity of 3,730.37%. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.86 billion. During the same period last year, the business earned $0.74 EPS. The company’s revenue was down 2.9% on a year-over-year basis. On average, analysts predict that Colgate-Palmolive will post 2.84 earnings per share for the current fiscal year.
Several brokerages have commented on CL. Argus raised their price target on shares of Colgate-Palmolive from $72.00 to $82.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research cut shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and set a $77.00 price target for the company. in a research report on Friday, June 7th. ValuEngine raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Macquarie raised their price objective on shares of Colgate-Palmolive from $65.00 to $72.00 and gave the company a “neutral” rating in a report on Monday, April 29th. Finally, Morgan Stanley raised their price objective on shares of Colgate-Palmolive from $62.00 to $68.00 and gave the company an “equal weight” rating in a report on Monday, April 29th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and five have issued a buy rating to the company’s stock. Colgate-Palmolive has a consensus rating of “Hold” and a consensus price target of $70.13.
COPYRIGHT VIOLATION WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.themarketsdaily.com/2019/06/14/tiemann-investment-advisors-llc-acquires-150-shares-of-colgate-palmolive-nysecl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
See Also: What is an overbought condition?
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.